Switch theme
Sign up to access all valuation multiples
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from EMEA and also has a presence in APAC, LATAM, and USA.
1997
949
LTM Revenue $291M
LTM EBITDA $50.8M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medartis has a last 12-month revenue (LTM) of $291M and a last 12-month EBITDA of $50.8M.
In the most recent fiscal year, Medartis achieved revenue of $270M and an EBITDA of $36.2M.
Medartis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medartis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $291M | XXX | $270M | XXX | XXX | XXX |
| Gross Profit | $232M | XXX | $215M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $50.8M | XXX | $36.2M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $20.9M | XXX | $8.7M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $8.5M | XXX | $4.2M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medartis's stock price is CHF 79 (or $95).
Medartis has current market cap of CHF 985M (or $1.2B), and EV of CHF 967M (or $1.2B).
See Medartis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | $0.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medartis has market cap of $1.2B and EV of $1.2B.
Medartis's trades at 4.3x EV/Revenue multiple, and 32.0x EV/EBITDA.
Equity research analysts estimate Medartis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medartis has a P/E ratio of 139.8x.
See valuation multiples for Medartis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 22.8x | XXX | 32.0x | XXX | XXX | XXX |
| EV/EBIT | 55.4x | XXX | 133.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 139.8x | XXX | 279.3x | XXX | XXX | XXX |
| EV/FCF | 32.5x | XXX | 46.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedartis's last 12 month revenue growth is 15%
Medartis's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Medartis's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medartis's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medartis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 34% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medartis acquired XXX companies to date.
Last acquisition by Medartis was XXXXXXXX, XXXXX XXXXX XXXXXX . Medartis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medartis founded? | Medartis was founded in 1997. |
| Where is Medartis headquartered? | Medartis is headquartered in Switzerland. |
| How many employees does Medartis have? | As of today, Medartis has 949 employees. |
| Is Medartis publicy listed? | Yes, Medartis is a public company listed on SWX. |
| What is the stock symbol of Medartis? | Medartis trades under MED ticker. |
| When did Medartis go public? | Medartis went public in 2018. |
| Who are competitors of Medartis? | Similar companies to Medartis include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medartis? | Medartis's current market cap is $1.2B |
| What is the current revenue of Medartis? | Medartis's last 12 months revenue is $291M. |
| What is the current revenue growth of Medartis? | Medartis revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Medartis? | Current revenue multiple of Medartis is 4.0x. |
| Is Medartis profitable? | Yes, Medartis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medartis? | Medartis's last 12 months EBITDA is $50.8M. |
| What is Medartis's EBITDA margin? | Medartis's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Medartis? | Current EBITDA multiple of Medartis is 22.8x. |
| What is the current FCF of Medartis? | Medartis's last 12 months FCF is $35.8M. |
| What is Medartis's FCF margin? | Medartis's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Medartis? | Current FCF multiple of Medartis is 32.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
